FDA approves expanded use of Octapharma's WILATE for surgery in patients with VWD.
“Rare Coagulopathies” chapter provides an overview of rare factor deficiencies and platelet disorders.
Apply now for the Prix Henri Chaigneau award, the winner to be announced at WHF's 2016 World Congress in Orlando, FL, July 2016.
Latest Medscape activity discusses emerging data for managing hemophilia and helps clinicians evaluate how to use them in clinical practice.
NHF is partnering with McMaster University, an international leader on clinical practice guidelines, to develop evidence-based guidelines for hemophilia care.
Bristol-Myers Squibb’s Daklinza™ (daclatasvir) combined with Gilead 's Sovaldi®,and AbbVie Inc.’s Technivie™ had high success rates in clearing hepatitis C virus.
New chapter covers assessment and management of typical bleeds, from joint bleeds to menorrhagia (heavy menstrual bleeding) and nosebleeds.
On July 8, 2015, the US Food and Drug Administration (FDA) set new rules to address drug shortages: a win for the bleeding disorders community.
Register now for these public workshops September 17 and 18 in Bethesda, MD. Hear the latest information on products and inhibitors.
Findings show that as people with hemophilia age, they will experience cardiovascular disease, which will need to be managed closely.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car